摘要
目的探讨血清NSE,CYFRA21_1,CA125,和TSGF联合检测对肺癌的诊断价值。方法应用ELISA技术,测定74例肺癌患者、40例肺良性疾病患者和20例体检正常者血清NSE、CYFRA21_1、CA125、TSGF的水平。结果肺癌组的4种标志物NSE、CYFRA21_1、CA125、TSGF的水平及检测阳性率均明显高于良性肺病及正常对照组(P<0.01)。鳞癌、腺癌和小细胞肺癌分别以NSE、CYFRA21_1、CA125、TSGF升幅较为明显。NSE、CYFRA21_1、CA125、TSGF的灵敏度分别为47.3%、54.0%、59.46%、55.4%,但4种联合检测的灵敏度为91.89%,明显优于1种血清肿瘤标志物的单项测定。结论血清NSE、CYFRA21_1、CA125、TSGF联合检测提高肺癌的阳性检出率和检测特异性,对肺癌的早期诊断、疗效监测、预后判断有重要意义。
Objective To study the clinical value for lung carcinoma by combining test of the serum levels Of NSE, CYFRA21-1, CA125 and TSGF. Methods NSE, CYFRA21-1, CA125 and TSGF in serum sample of 74 patients with lung carcinoma,40 cases with benign lung disease and 20 healthy people were determined by using ELISA. Results The serum levels and the positive rate of NSE, CYFRA21-1, CA125 and TSGF were higher in the lung carcinoma group than those in the benign lung disease group with a high statistical significance （ P 〈 0.01 ）. NSE CYFRA21-1, CA125 and TSGF, NSE increased significantly in serum of adenocarcinoma , squamous lung carcinoma and small-cell lung carcinoma respectively. The positive rates of detection one, two, three or four tumor markers were 47.3 %, 54.0 %, 59.46 % and 55.4 % respectively. The sensitivity of the combination with NSE, TSGF, CA125 and CYFRA21-1 were 91.89%. Conclusions The positive rate maybe increased by combining test ot NSE CYFRA21-1, CA125 and TSGF in lung carcinoma but not in benign lung diseases .Thus the combining test might be of high value for the early diagnosis, improving the therapeutic effect and prognosis of lung carcinoma.
出处
《肿瘤基础与临床》
2006年第1期16-18,共3页
journal of basic and clinical oncology
